Abstract

Background: LiveWell Initiative LWI is a self-funded nonprofit social enterprise which thrives on innovation.

The organization has, for 5 years, supervised MPH and DrPH Practicums for the Harvard T. H. Chan School of Public Health, Harvard University, Boston USA. It also supervises PhD thesis at University of Helsinki, Finland. At the inception of COVID-19, LWI designed and compiled three (3) sets of study protocols in response to the COVID-19 response in Africa with a goal to arriving at a practical and affordable solution to the pandemic using 4-Aminoquinolines.

Method: A concurrent cohort/descriptive study of observation in patients exposed to HCQ/CQ Prophylaxis  and Treatment with HCQ/CQ and Quinine with categorization as specified as Not critically ill, critically ill but not on a ventilator and critically ill on a ventilator.  One hundred and twenty-three (123) subjects were categorized into shelter-in-place, self-quarantine and self-isolation (Not critically ill, critically ill but not on a ventilator and critically ill on a ventilator). The 4-Aminoquinolines were administered with macrolide and zinc sulphate as appropriate for a defined duration and doses.

Results: The preliminary study of the 123 subjects covering all categories listed above resulted in 100% positive outcomes; Nil death, Nil relapse in Symptomatic persons and Total recovery with no relapse after 6 weeks lockdown, and asymptomatic persons post-prophylaxis, after 6 weeks lockdown. The results have been gathered principally from Clinician Reported Outcomes with a few Patient Reported Outcomes.

Conclusion: These repurposed drugs with unique strengths- Chloroquine and its analogue Hydroxychloroquine as well Quinine, hold away in the treatment of COVID-19.

Keywords: 4-Aminoquinolines; Zinc Sulphate; COVID-19; Ventilator; Pandemic; Repurposing; Ionophore